Insulin-mediated glycogen synthase activity in skeletal muscle correlates with the rate of insulin-mediated glycogen deposition and is reduced in human subjects with insulin resistance. To assess the role of glycogen synthase phosphatase as a possible mediator of reduced glycogen synthase activity, we studied 30 Southwestern American Indians with a broad range of insulin action in vivo. Percutaneous biopsies of the vastus lateralis muscle were performed before and during a 440-min euglycemic clamp at plasma insulin concentrations of 89±5 and 1,470±49,gU/ml (mean±SEM); simultaneous glucose oxidation was determined by indirect calorimetry. After insulin stimulation, glycogen synthase activity was correlated with the total and nonoxidative glucose disposal at both low (r = 0.73, P < 0.0001; r = 0.68, P < 0.0001) and high (r = 0.75, P < 0.0001; r = 0.74, P < 0.0001) plasma insulin concentrations. Fasting muscle glycogen synthase phosphatase activity was correlated with both total and nonoxidative glucose disposal rates at the low (r = 0.48, P < 0.005; r = 0.41, P < 0.05) and high (r = 0.47, P < 0.05; r = 0.43, P < 0.05) plasma insulin concentrations. In addition, fasting glycogen synthase phosphatase activity was correlated with glycogen synthase activity after low-(r = 0.47, P < 0.05) and high-(r = 0.50, P < 0.01) dose insulin stimulations. These data suggest that the decreased insulin-stimulated glucose disposal and reduced glycogen synthase activation observed in insulin resistance could be secondary to a low fasting glycogen synthase phosphatase activity.
Introduction
In vivo, insulin-stimulated skeletal muscle glycogen synthase activity is correlated with the rate of insulin-mediated glucose disposal in man (1) , and these two parameters decreased in subjects with insulin resistance (2, 3) . Glycogen synthase is the rate-limiting enzyme for glycogen synthesis (4) . Its activity can be modulated by allosteric or covalent (phosphorylation or dephosphorylation) modifications of the molecule (5, 6) . The dephosphorylated form (I form) is spontaneously active and virtually independent from the allosteric activation by glucose-6-phosphate (G6P);' the phosphorylated form (D form) is inactive and sensitive to the action of the allosteric activator, G6P. The change from the dephosphorylated to the phosphorylated state is carried out by several protein kinases (5, 6) ; the inverse reaction is catalyzed by glycogen synthase phosphatase (protein phosphatase) (7) . Insulin enhances glycogen synthase activity by a mechanism involving the activation of glycogen synthase phosphatase (8) (9) (10) and the inhibition of cAMP-dependent protein kinase (11, 12) . The inhibition of this kinase has recently been reported to lower the phosphorylation of inhibitor-1, leading to the activation of glycogen synthase phosphatase (7) .
Several studies using animal models of diabetes mellitus (13) (14) (15) (16) (17) (18) have shown that diminished insulin or glucose-stimulated glycogen synthase activities are associated with decreased levels of glycogen synthase phosphatase. Such results have not been reported on human muscle. In this study, we measured fasting human muscle glycogen synthase phosphatase activity to determine its relationship with insulin-stimulated glycogen synthase activity.
Methods
30 Southwestern American Indians, 11 women and 19 men, were admitted to the clinical research ward of the Clinical Diabetes and Nutrition Section to be studied. They were selected to represent a broad range of insulin sensitivity. Their characteristics are shown in Table I . After giving written informed consent, each subject underwent a complete physical examination and an electrocardiogram. After an overnight fast, blood was drawn for complete blood count, liver function tests, blood-urea nitrogen, creatinine, electrolytes, calcium, total plasma protein, albumin, prothrombin, and partial thromboplastin times. Urinalysis was also performed. None ofthe subjects were taking any medication and all had a normal physical examination, electrocardiogram, and blood and urine analyses. After being on a weightmaintaining diet for at least 2 d (20% protein, 50% carbohydrate, and 30% fat), each subject had an oral glucose tolerance test (19), and the next morning after a 10-h overnight fast, a hyperinsulinemic euglycemic clamp was performed. Body fat was estimated in each subject by underwater weighing with simultaneous measurement of residual lung volume (20) .
Euglycemic clamp (Fig. 1) . After a 10-h overnight fast, an intravenous catheter was placed in an antecubital vein Cl =1 perglycemic subjects, the glucose infusion was not begun until the plasma glucose concentration had declined to 100 mg/dl. Blood for plasma glucose determination was drawn every 10 min until the start of the glucose infusion in the hyperglycemic patients, and then every 5 min throughout the rest of the test, as for the remaining patients. The mean plasma glucose concentration for all subjects was 103±0.5 mg/dl (mean CV = 2.5±0.3%) during the 300-340-min period of the lowdose insulin infusion and was 103±0.5 mg/dl (mean CV = 3.9±0.3%) between 400 and 440 min of the high-dose insulin infusion. Blood for plasma 3-[3HJglucose specific activity determination was drawn every 10 min from 300 to 340 min to calculate the glucose appearance rate (see below).
Indirect calorimetry. Starting at 280 min of the low-dose insulin infusion for the rest of the clamp, indirect calorimetric measurements were performed as follows: a clear plastic, ventilated hood was placed over the subject's head. Room air was drawn through the hood and its flow rate measured by a pneumotachograph (Gould Inc., Recording Systems Div., Cleveland, OH). A constant amount of expired air mixed with room air within the hood was aspirated and analyzed for its carbon dioxide and oxygen fractions. The oxygen analyzer was a Zirconium cell analyzer and the carbon dioxide analyzer was an infrared analyzer (both by Applied Electrochemistry Inc., Sunnyvale, CA). The gas analyzers and the flowmeter were connected to a desktop computer (Hewlett-Packard Co., Palo Alto, CA). The computer recorded continuous, integrated, 5-min calorimetric measurements used for calculations between 300 and 340 and 400 and 440 min, according to the start of the insulin infusion. The protein oxidation rate during the test was estimated from urea nitrogen production rate measured in the urine collected during the clamp. The nonprotein respiratory quotient was then calculated and the substrate oxidation rates were determined from the equations of Lusk (22) .
Muscle biopsy, glycogen synthase, and glycogen synthase phosphatase determination. During the 15 min before the start of the insulin infusion, the first of three percutaneous muscle biopsies of the vastus lateralis muscle was performed with local anesthesia. The samples were collected in two or three passes with a Bergstrom (Depuy, Phoenix, AZ) muscle biopsy needle, to which vacuum was applied by a 60-ml syringe via a 100-cm plastic connecting tube. The specimens were frozen in liquid nitrogen within 15 s.
The second muscle biopsy was performed on the contralateral thigh between 340 and 360 min, while insulin continued to be infused at the same speed and the glycemia was controlled; the third muscle biopsy was performed between 440 and 460 min at a site that was 10 cm more proximal than the first muscle biopsy. 10 times more insulin continued to be infused than was infused during the second muscle biopsy.
The samples were stored at -70'C and assayed later for glycogen synthase activity (2 
Results
Glycogen synthase (Table II) . Muscle glycogen synthase activities obtained before insulin infusion ranged from 0.12 to 0.64 U/g wet wt. The insulin-stimulated glycogen synthase activities were positively correlated with the respective mean total and nonoxidative insulin-stimulated glucose disposal rates at the end of the low (r = 0.73, P <0.0001; r = 0.68, P <0.0001, respectively) and the high (r = 0.75, P < 0.0001; r = 0.74, P < 0.0001) insulin infusion rates (Fig. 2, A and B) .
Total glycogen synthase activity was unchanged from the fasting (0.64±0.03 U/g wet wt) to the low-dose insulin-stimulated state (0.69±0.03 U/g wet wt), but increased between the fasting and the high-dose insulin-stimulated conditions (0.72±0.03 U/g wet wt, P < 0.01). Fasting glycogen synthase and total glycogen synthase activities were not correlated with low or high-dose insulin-stimulated total and nonoxidative glucose disposal rates.
Glycogen synthasephosphatase. Fasting phosphatase activity ranged from 0.25 to 1.53 U/g wet wt and was positively correlated with total and nonoxidative insulin-mediated glucose disposal rates at both low (r = 0.48, P < 0.05; r = 0.41, P < 0.05, respectively) and high (r = 0.47, P < 0.05; r = 0.43, P < 0.05, respectively) rates of insulin infusion (Fig. 3, A  and B) .
Fasting phosphatase activities were also positively correlated with the glycogen synthase activities measured at the end of the low (r = 0.47, P < 0.05) and high (r = 0.50, P < 0.01) rates of insulin infusion (Fig. 4, A the low and high rates of insulin infusion, respectively. Phosphatase activity measured at the end of the low rate of insulin infusion (mean = 0.93±0.04 U/g wet wt) was not increased but did correlate with the low dose insulin-stimulated glycogen synthase activity (r = 0.43, P < 0.05, data not shown) but not with the low-dose, insulin-stimulated glucose disposal rate. Phosphatase activity measured at the end of the high rate of insulin infusion (mean = 0.91±0.05 U/g wet wt) was not significantly different from fasting activity and was not correlated with either synthase activity or insulin-stimulated glucose disposal rates.
Discussion
We previously reported (2) that insulin-stimulated glucose disposal rates (and nonoxidative glucose disposal rates) were correlated with insulin-stimulated skeletal muscle glycogen synthase activity in vivo in man; glycogen synthase activities also correlated with insulin-stimulated muscle glycogen accretion. In this study, we determined the relationship between insulinstimulated muscle glycogen synthase and glycogen synthase phosphatase activities. Firstly, our results confirm the relationship between insulin-stimulated total and nonoxidative glucose disposal and muscle glycogen synthase activity. Secondly, they show that in human muscle, fasting glycogen synthase phosphatase activity is linearly correlated with physiologically and maximally insulin-stimulated total and nonoxidative glucose disposal and glycogen synthase activity. The subjects whose glycogen synthase is least activated by insulin are those with the lowest fasting glycogen synthase phosphatase levels.
A recent in vivo study in Caucasians with normal glucose tolerance (1) confirmed our previously reported data (2) showing that the rate of insulin-stimulated nonoxidative glucose disposal correlated with insulin-stimulated muscle glycogen synthase activity. Muscle glycogen synthase is also less activated by insulin in type I diabetic human subjects, in whom total glycogen synthase activity is not reduced (26). To our knowledge, however, human glycogen synthase phospha- tase has only been measured in PMN (27, 28 (14, 17) in animal experiments. Decreased glycogen synthase phosphatase and reduced insulin-stimulated glycogen synthase activities have also been observed after fasting in rat heart (30, 31) .
In diabetic animals, acute in vitro activation of glycogen synthase can be recovered, at least partly, by previous in vivo (15) (16) (17) 29) or in vitro (13, 14) insulin treatment; this is associated with restored normal levels of glycogen synthase phosphatase, reached in 1-68 h (16, 17) . Inhibitors of protein synthesis, administered with insulin in vivo (17) or in vitro (13) , prevent glycogen synthase phosphatase of diabetic tissue from reaching control levels, and they prevent the acute reactivation of glycogen synthase by insulin, whereas total glycogen synthase is not influenced.
Based on animal studies, lower fasting glycogen synthase phosphatase levels in man may be the result of (a) abnormal regulator activity (inhibition and/or activation), (b) an abnormal substrate, or (c) a decreased amount of the enzyme.
Glycogen synthase phosphatase may be inhibited (27, 32, 33) by phosphorylase a, the active form of phosphorylase; this regulation mechanism of glycogen synthase phosphatase is controversial (16, 34 here. This could account for the results generated by lowering glycogen synthase phosphatase activity.
In vivo, glycogen synthase may be a less suitable substrate for glycogen synthase phosphatase (18, 31, 38); because we assayed human muscle glycogen synthase phosphatase using purified rabbit glycogen synthase D, the latter phenomenon is unlikely to explain our results.
That protein synthesis inhibitors prevent (13, 17) insulin from restoring normal levels of glycogen synthase phosphatase (13) (14) (15) (16) (17) (14, 17) . Results on acute insulin stimulation of phosphatase, however, have been varied (9, 14, 17, 30) . Insulin stimulation of phosphatase activity was observed in rat skeletal muscle 10 min after insulin injection (9) and up to 30 min after insulin injection in rat heart muscle after starvation (30) . Other studies in rat heart (17) 
